Exponent (EXPO) CEO receives 17,814 restricted stock units as equity award

Rhea-AI Filing Summary

Exponent Inc. President and CEO Catherine Corrigan received a grant of 17,814 restricted stock units on March 13, 2026. These RSUs are a form of equity compensation and are directly owned. Each unit is exchangeable on a 1-for-1 basis into Exponent common stock. Following this award, Corrigan holds 17,814 RSUs tied to an equivalent number of underlying common shares, with a stated conversion and expiration date of March 13, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Corrigan Catherine

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	17,814	$0.00	--

Holdings After Transaction: Restricted Stock Units — 17,814 shares (Direct)

Footnotes (1)

1. 1-for-1. Not applicable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Corrigan Catherine

(Last) (First) (Middle)

149 COMMONWEALTH DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXPONENT INC [ EXPO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/13/2026		A		17,814		03/13/2030	03/13/2030	Common Stock	17,814	(2)	17,814	D

Explanation of Responses:

1. 1-for-1.

2. Not applicable.

	By: Wendy Whitehouse For: Catherine Corrigan	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Exponent (EXPO) CEO Catherine Corrigan report in this Form 4?

Catherine Corrigan reported receiving 17,814 restricted stock units as equity compensation. The units are directly owned and each is linked to one share of Exponent common stock, reflecting a non-cash grant rather than an open-market stock purchase or sale.

How many restricted stock units did Exponent (EXPO) grant to its CEO?

Exponent granted CEO Catherine Corrigan 17,814 restricted stock units. These RSUs correspond to 17,814 underlying common shares on a one-for-one basis, giving her additional equity exposure through stock-based compensation instead of a cash salary or open-market share transaction.

Is the Exponent (EXPO) CEO’s Form 4 transaction a stock purchase or sale?

The transaction is not a stock purchase or sale. It is a grant/award acquisition of 17,814 restricted stock units provided as compensation at a reported price of $0.00 per unit, rather than an open-market trade involving cash outlay or proceeds.

When can the Exponent (EXPO) CEO’s restricted stock units convert into common stock?

The filing lists a conversion and expiration date of March 13, 2030 for the 17,814 restricted stock units. Each RSU is linked on a 1-for-1 basis to Exponent common stock, tying the CEO’s award directly to the company’s equity over this period.

How many derivative securities does the Exponent (EXPO) CEO hold after this Form 4?

After this reported transaction, Catherine Corrigan holds 17,814 restricted stock units as derivative securities. The filing shows no additional remaining derivative positions beyond this award, and there were no reported stock option exercises, sales, gifts, or tax-withholding dispositions in this Form 4.